Dupont Capital Management’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Dupont Capital Management’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-20,443	Closed	-$1.16M	–	1436
2019 Q4	$1.16M	Sell	20,443 -770	-4%	-$40.8K	0.03%	527
2019 Q3	$1.14M	Sell	21,213 -2,275	-10%	-$132K	0.03%	485
2019 Q2	$1.4M	Buy	23,488 +13,520	+136%	+$851K	0.03%	458
2019 Q1	$621K	Hold	9,968	–	–	0.01%	692
2018 Q4	$604K	Buy	+9,968	New	+$596K	0.01%	671
2018 Q1	–	Sell	-15,316	Closed	-$664K	–	1036
2017 Q4	$664K	Hold	15,316	–	–	0.02%	599
2017 Q3	$713K	Hold	15,316	–	–	0.02%	593
2017 Q2	$758K	Buy	15,316 +6,567	+75%	+$344K	0.02%	588
2017 Q1	$479K	Hold	8,749	–	–	0.01%	709
2016 Q4	$487K	Hold	8,749	–	–	0.01%	680
2016 Q3	$400K	Hold	8,749	–	–	0.01%	594
2016 Q2	$349K	Buy	+8,749	New	+$320K	0.01%	623
2016 Q1	–	Sell	-5,113	Closed	-$220K	–	721
2015 Q4	$220K	Hold	5,113	–	–	0.01%	627
2015 Q3	$223K	Buy	+5,113	New	+$276K	0.01%	577

Other funds holding BSTC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Dupont Capital Management's BSTC Position: Q1 2020 in Review

Dupont Capital Management sold out of BioSpecifics Technologies Corp. (BSTC) in Q1 2020, closing a stake of 20,443 shares — an estimated $1.16M sold.

Dupont Capital Management first reported a position in BSTC in Q3 2015 and held it in 14 quarters. The position peaked at $1.4M in Q2 2019. 113 funds tracked by Wall St. Rank hold BSTC as of Q1 2020.

Dupont Capital Management reported no remaining BioSpecifics Technologies Corp. position as of Q1 2020 after selling out during the quarter.
Dupont Capital Management sold 20,443 BioSpecifics Technologies Corp. shares in Q1 2020, an estimated $1.16M.
Dupont Capital Management first reported a position in BioSpecifics Technologies Corp. in Q3 2015 and held it in 14 quarters.
Dupont Capital Management's BioSpecifics Technologies Corp. position peaked at $1.4M in Q2 2019.
113 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q1 2020.

Based on Dupont Capital Management's 13F filing for Q1 2020, filed 29 Apr 2020.